Innovative Drugs Driven by Policy and Clinical Progress

China’s innovative drugs sector continues to accelerate under policy support, clinical progress, and global collaboration, reshaping the international pharmaceutical landscape.

Top Stories

Recurrent Respiratory Infections with Malnutrition and Growth Delay — Beware of the Rare Pediatric Disease: Cystic Fibrosis (CF)

China’s First IL-1β Monoclonal Antibody Approved: Firsekibart Brings New Breakthrough to Gout Treatment

Latest Coverage

Global Pharmaceutical Market Under Policy Influence: Reshaping the Landscape and Future Opportunities
Hong Kong Dengyue Medicine learned that Against the backdrop of steadily growing global healthcare demand and acceler...

Complete Guide for Early Cancer Screening｜A Review of Screening Methods for 6 Common Cancers
Compiled by DengYueMed based on publicly available medical guidelines and screening consensus.

Proposed Breakthrough Therapy Designation: Keymed’s CM336 Poised to Reshape the Treatment Landscape of AL Amyloidosis
On April 28, 2026, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) re...

cadonilimab in pancreatic cancer: immunotherapy breakthrough at aacr 2026
Breakthrough in Pancreatic Cancer Immunotherapy: PD-1/CTLA-4 Bispecific Antibody Cadonilimab Shows Promising Signals ...

Targeting TL1A in Immune-Mediated Inflammatory Diseases: From an Inflammatory Amplifier to a New Strategy for Precision Intervention
In the field of immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease (IBD), rheumatoid a...

HLX43: A Next-Generation PD-L1-Targeted ADC Breaking Traditional Limitations in Cancer Therapy
As oncology continues to evolve toward precision medicine and multi-mechanism synergy, antibody-drug conjugates (ADCs...

In-Depth Analysis

Innovative Drugs Driven by Policy and Clinical Progress

Recurrent Respiratory Infections with Malnutrition and Growth Delay — Beware of the Rare Pediatric Disease: Cystic Fibrosis (CF)

China’s First IL-1β Monoclonal Antibody Approved: Firsekibart Brings New Breakthrough to Gout Treatment

Global Pharmaceutical Market Under Policy Influence: Reshaping the Landscape and Future Opportunities